Drugs / Echinacea purpurea

Trials 4 · a red edge is where a trial was stopped

2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00010465 ? → Dec 2002 otitis media National Center for Complementary and Integrative Health (NCCIH) Completed No outcome recorded
Phase 31 trial
Phase 3 NCT02971384 Nov 2016 → Aug 2017 viral respiratory tract infection A. Vogel AG Completed No outcome recorded
Phase 42 trials
Phase 4 NCT05002179 Nov 2020 → May 2021 common cold A. Vogel AG Completed No outcome recorded
Phase 4 NCT00103012 Jan 2005 → Jan 2011 National Institutes of Health Clinical Center (CC) Completed No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT01129128 Comparator May 2010 → Mar 2011 respiratory tract infectious disorder University of Washington Completed No outcome recorded
NCT00860795 Comparator Mar → Aug 2009 respiratory tract infectious disorder University of Washington Completed No outcome recorded
NCT00773435 Comparator Nov 2008 → May 2009 respiratory tract infectious disorder University of Washington Withdrawn No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Echinacea purpurea “An alcohol extract of Echinacea purpurea roots and seeds (or placebo) was administered for 10 days at the first sign of each common cold.” PMID 18831749 Oct 2008
4

NCT00860795

NCT00773435

NCT01129128

NCT00103012

Known as Echinaforce ClinicalTrials.gov intervention name — accepted as the source's own label NCT02971384
1

NCT05002179

Modality Traditional medicine (herbal / TCM) “herbal preparation (Echinacea purpurea)” NCT00103012
Route Oral “5 ml by mouth 3 times per day for 10 days” NCT01129128